Home / Companies / News / Covid-19: Zydus gets SEC approval for two-dose regimen of ZyCov-D

Covid-19: Zydus gets SEC approval for two-dose regimen of ZyCov-D

Zydus to conduct mixing trials to test vax efficacy after two shots of Covishield/Covaxin

Premium

Zydus Lifesciences supplies its three-dose deoxyribonucleic acid (DNA) vaccine — ZyCoV-D — to the Centre at Rs 265 per dose and the needle-free applicator device at Rs 93 per dose.

Sohini Das Mumbai

3 min read Last Updated : Apr 15 2022 | 2:25 AM IST

Zydus Lifesciences’ (formerly known as Cadila Healthcare) three-dose Covid vaccine — ZyCoV-D — has received the subject expert committee (SEC) approval for a two-dose regimen, according to sources close to the development.

The pharmaceutical company, however, declined to comment on the matter.

Approval for the two-dose regimen may boost the offtake of the vaccine not yet available in the private market.

Zydus Lifesciences supplies its three-dose deoxyribonucleic acid (DNA) vaccine — ZyCoV-D — to the Centre at Rs 265 per dose and the needle-free applicator device at Rs 93 per dose. It had an order for 10 million doses from

Topics : Coronavirus Vaccine Zydus Lifesciences indian government Cadila Healthcare

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in